FTC sues to block Amgen's Horizon acquisition; Amgen vows to fight

AMGEN INC

FTC filed complaint in federal court seeking to enjoin acquisition of Horizon Therapeutics.
Amgen calls FTC's bundling theory 'entirely speculative' and says no prior deal blocked on that theory.
Amgen committed not to bundle Horizon products at issue, but FTC still proceeded with lawsuit.
Amgen intends to work with court to close transaction by mid-December.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.